Table 3.
Estimates of the Effect of Gender, Age, Treatment, Fibrosis Stage, and IDU on Mortality, From Multivariable Cox Regression Models (A) for All-Cause Mortality and (B) for Cause-Specific Mortality
| A, All-Cause Mortality | ||||||
|---|---|---|---|---|---|---|
| Total: 4700 Persons | All-Cause (478 Deaths) |
|||||
| Sex | Male Female |
P < .001 1.0 (ref) 0.68 (0.56−0.84) |
||||
| Age at baseline, y | 20 40 60 |
P < .001 0.6 (0.37−0.97) 1.0 (ref) 2.51 (2.04−3.1) |
||||
| Treatment status | Never treated Treated with DAA, SVR Treated with DAA, failure Treated with IFN, SVR Treated with IFN, failure |
P < .001 1.0 (ref) 0.24 (0.09−0.63) 0.86 (0.27−2.75) 0.34 (0.25−0.46) 0.86 (0.69−1.06) |
||||
| Fibrosis score | F0, F1, or F2 F3 or F4 |
P < .001 1.0 (ref) 3.62 (2.92−4.49) |
||||
| IDU | Never Ever |
P < .001 1.0 (ref) 2.01 (1.57−2.58) |
||||
| B, Cause-Specific Mortality | ||||||
| Total: 4700 Persons | Liver Failure (114 Deaths, 23.8%) |
Liver Cancer (89 Deaths, 18.6%) |
Nonliver Cancer (72 Deaths, 15.1%) |
Cardiovascular (33 Deaths, 6.9%) |
Unnatural Cause (65 Deaths, 13.6%) |
|
| Sex | Male Female |
P = .17 1.0 (ref) 0.75 (0.49−1.14) |
P = .097 1.0 (ref) 0.67 (0.42−1.08) |
P = .073 1.0 (ref) 0.61 (0.36−1.05) |
P = .043 1.0 (ref) 0.44 (0.2−0.97) |
P = .18 1.0 (ref) 0.68 (0.39−1.19) |
| Age at baseline, y | 20 40 60 |
P = .019 0.27 (0.08−0.93) 1.0 (ref) 2.06 (1.25−3.42) |
P < .001 0.09 (0.01−0.63) 1.0 (ref) 6.23 (2.72−14.24) |
P < .001 0.05 (0.01−0.28) 1.0 (ref) 8.34 (3.96−17.58) |
P < .001 0.64 (0.07−5.47) 1.0 (ref) 5.4 (2.13−13.72) |
P = .045 2.9 (1.21−6.9) 1.0 (ref) 1.06 (0.61−1.86) |
| Treatment status | Never treated Treated with SVR Treated with failure |
P < .001 1.0 (ref) 0.18 (0.08−0.37) 0.78 (0.51−1.18) |
P < .001 1.0 (ref) 0.33 (0.16−0.71) 1.34 (0.81−2.22) |
P = .27 1.0 (ref) 0.59 (0.31−1.11) 0.84 (0.47−1.49) |
P = .18 1.0 (ref) 0.42 (0.15−1.12) 0.61 (0.26−1.41) |
P = .17 1.0 (ref) 0.5 (0.24−1.03) 0.89 (0.48−1.67) |
| Fibrosis score | F0, F1, or F2 F3 or F4 |
P < .001 1.0 (ref) 13.8 (7.69−24.75) |
P < .001 1.0 (ref) 14.09 (6.59−30.13) |
P = .12 1.0 (ref) 1.52 (0.9−2.58) |
P = .0095 1.0 (ref) 2.81 (1.29−6.14) |
P = .028 1.0 (ref) 1.91 (1.07−3.4) |
| IDU | Never Ever |
P = .26 1.0 (ref) 1.31 (0.82−2.11) |
P = .19 1.0 (ref) 1.46 (0.83−2.56) |
P < .001 1.0 (ref) 3.22 (1.64−6.33) |
P = .17 1.0 (ref) 2.12 (0.73−6.18) |
P = .0011 1.0 (ref) 3.65 (1.67−7.97) |
Abbreviations: DAA, direct-acting antiviral agent; IDU, injection drug use; IFN, interferon; SVR, sustained virologic response.